

MEDIA BACKGROUNDER

Canadian highlights at BIO

Tuesday June 28, 2011

10:30 am – Canadian Pavilion Opening

Political leaders from throughout Canada joined to celebrate the excellence and value of biotechnology and the bio-economy in Canada. The official ceremony includes remarks of welcome from the federal and provincial ministers and government officials who helped to lead the Canadian delegation in BIO.

4pm – Gold Leaf Awards

Celebrating the best in Canadian biotechnology innovation, these awards are presented to both companies and individuals for their achievements in 2010. This year, BIOTECanada received 66 nominations showcasing Canada's best in biotechnology. The awards presentation will lead into a reception hosted by BioQuébec in the Canada Café.

2011 Winners

Company of the Year – Cardiome Pharma Corp

Industry Leadership Award – Yves Rosconi

Early Stage Company of the Year (Health) – Allon Therapeutics Inc.

Early Stage Company of the Year (Industrial) – EnWave Corporation

Contribution to Canadian Communities – Sanofi Pasteur Limited

Contribution to the Association – Gordon Jans, PwC

6pm – Canadian Soiree (Canadian Embassy)

BIOTECanada along with our Canadian and international partners are pleased to host the Canada Soiree. This international invitation-only event brings together members of the biotechnology community from around the world.

SHOWCASING CANADA

Boasting a long history of groundbreaking scientific achievements and discoveries, Canada is an attractive, rapidly growing biotech powerhouse. From environmental technologies to new vaccines, from industrial manufacturing and clean tech to novel foods, from animal health technologies to agricultural innovation, from human health research and development to renewable fuels, Canada has built a national network of thriving biotech clusters.



Vaccines – Historical Success Meets Innovation

Featuring Bioniche, Medicago, Sanofi Pasteur and VIDO.

Canada's Bioniche Life Sciences Inc. holds the patent to the world's first E. coli vaccine. Trademarked Econiche, the vaccine works by enabling a treated cow to produce antibodies that block proteins secreted by the dangerous strain of bacteria as it attempts to take up residence in the intestinal wall. Because the bacteria are blocked from attaching to the cell wall, they die, rather than congregate and multiply. The theory behind reducing E. coli levels in cows is that it will reduce the amount an animal "sheds" into the environment, in turn making E. coli contamination less likely in the food chain. Contact Jennifer Shea, 613-391-2097.

Medicago has developed two proprietary technologies for the development of vaccines: its plant-based Proficia and Virus-Like Particles. Medicago is committed to providing effective and affordable vaccines. They are developing vaccines to protect against H5N1 pandemic influenza, using a transient expression system, which produces recombinant vaccine antigens in non-transgenic plants. This plant technology is uniquely capable of efficient protein expression at very high yields. Contact, Andy Sheldon 418-658-9393.

Sanofi-Pasteur has a strong history of developing and marketing innovative vaccines for the prevention and treatment of disease and by playing an active role in the immunization community to maximize vaccination. Sanofi-Pasteur has made a strategic decision to remain in Canada, developing their cancer vaccine, investing \$600 million since 2000. Contact, Nancy Simpson 416-667-2955.

In the heartland of the Canadian Prairies, the largest vaccine research investment to date in Canada, Vaccine and Infectious Disease Organization is set to open providing critical research infrastructure to help protect humans and animals from infectious diseases. Since 1975, the Centre has commercialized eight vaccines, six of which were world firsts. Having a facility to accommodate livestock allows scientists to work closely with livestock stakeholders to enhance the health of their animals. Contact, Shirly Toms 306-966-7483.



Partnerships Abound – Outstanding Science Leads Stem Cell Knowledge

Dr. Mick Bhatia, Director and Senior Scientist of McMaster's Stem Cell and Cancer Research Institute is heading up a team of Canadian scientists who have transformed pinches of human skin into petri dishes of human blood – a major medical breakthrough that could yield new sources of blood for transfusions after cancer treatments or surgery. The discovery, by Dr. Bhatia and researchers at McMaster University could one day potentially allow anyone needing blood after multiple rounds of surgery or chemotherapy, or for blood disorders such as anemia, to have a backup supply of blood created from a tiny patch of their own skin – eliminating the risk of their body's immune system rejecting blood from a donor. Contact, Julie McBride 905-525-9140 x28685.

Renewing Global Energy and Food Supply with Unparalleled Biomass and Novel Foods


Canada's sheer size allows for a strategic advantage when it comes to greening of our bio-economy. Industry trending shows us an emerging crop of dedicated entrepreneurs who have been reaping benefits of Canada's unparalleled biomass (7% of global land area, 10% of world forest). The reality of our collective industrial biotech revolution is staggering. Agrisoma is one of Canada's longest running agricultural biotechnology companies. Launched in 2001, Agrisoma has steadily honed its technology and product focus to position itself as a provider of sustainable solutions for meeting the demand for "renewable oils" for displacing petroleum use in powering commercial transportation and other markets. Agrisoma is commercializing bio based jet fuel from agriculture crops. They believe they can break commercial transportation's petroleum habit by using a little known non-food crop (Carinata) and biotechnology to make renewable fuels. Contact, Steve Fabijanski 613-724-0704



GENERAL BACKGROUNDER


Canada stands out as one of the most diversified bio-economies in the world. From our early leadership in agricultural biotechnology research and commercial development, to today where we have world-class leadership in vaccines, therapeutic treatments for debilitating illnesses, renewable energy, bio-manufacturing and environmental remediation technologies. Building out of the recent economic downturn the bio-economy in Canada has continued to grow. With more than 7% of our national GDP being generated every year as a result of biotechnology development and use, all regions of Canada are realizing the benefits of this growth.

THE CANADIAN BIO-ECONOMY



Sources: Source Data - Statistics Canada, CANSIM Table 379-0027
 Methodology - Industrial Biotechnology. December 1, 2008, 4(4): 363-366. doi:10.1089/ind.2008.4.363

2010 GDP ANALYSIS



Sources: Source Data - Statistics Canada, CANSIM Table 379-0027
 Methodology - Industrial Biotechnology. December 1, 2008, 4(4): 363-366. doi:10.1089/ind.2008.4.363

